{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:42:50Z","timestamp":1790473370639,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Achievement of lipid targets is crucial in patients with type 2 diabetes mellitus (T2DM) to mitigate the risk of cardiovascular diseases (CVD). Data on lipid-control status among patients with T2DM in Bangladesh are scarce. This study was conducted to determine the lipid-control status among patients with T2DM who were on lipid-lowering drugs in the country.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This cross-sectional study was conducted in the diabetes outpatient departments of several tertiary hospitals in Bangladesh from January 2022 to December 2022. Adults of both sexes diagnosed with T2DM for at least one year and were on the lipid-lowering drug(s) for a minimum of 3\u00a0months were included in the study by consecutive sampling. Patients\u2019 data were collected by face-to-face interviews, and blood samples were collected for fasting lipid profile. The lipid target was set at\u2009&lt;\u2009200\u00a0mg\/dL for total cholesterol (TC),\u2009&lt;\u2009150\u00a0mg\/dL for triglyceride (TG),\u2009&lt;\u2009100\u00a0mg\/dL for low-density lipoprotein cholesterol (LDL-C),\u2009&gt;\u200940\u00a0mg\/dL for high-density lipoprotein cholesterol (HDL-C), and\u2009&lt;\u2009160\u00a0mg\/dL for non-HDL cholesterol (non-HDL-C).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>Three thousand sixty patients (age 44.7\u2009\u00b1\u200913.3\u00a0years, female 57%) with T2DM were evaluated. Overall, almost 81% of the study subjects achieved the LDL-C target. Besides, TC, TG, HDL-C, and non-HDL-C targets were achieved by 40.8, 21.6, 66.3, and 44.1% of patients, respectively. However, all the lipid parameters were under control in only 8.8% of patients. Almost 77.6% of the patients with ischemic heart disease, 81.5% of patients with stroke, and 65% of patients with CKD had LDL levels\u2009&lt;\u200970\u00a0mg\/dL. Only 10.03% achieved the HbA1c target of\u2009&lt;\u20097%. 7.4% of patients achieved both HbA1c\u2009&lt;\u20097% and LDL\u2009&lt;\u2009100\u00a0mg\/dL and 5% achieved both HbA1c\u2009&lt;\u20097% and LDL\u2009&lt;\u200970\u00a0mg\/dL. Advanced age (aOR 0.97, 95% CI 0.96, 0.98, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), longstanding T2DM (aOR 0.53, 95% CI 0.39, 0.72, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and non-statin therapy (aOR 0.25, 95% CI 0.16, 0.37, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) were negatively associated with lipid control (LDL\u2009&lt;\u2009100\u00a0mg\/dL) while using oral hypoglycemic drugs or insulin (aOR 2.01, 95% CI 1.45, 2.77, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and having cardiovascular comorbidity (aOR 3.92, 95% CI 3.00, 5.12, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) were positively associated with lipid control.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Though most patients with T2DM achieved their target LDL level, the prevalence of both glycemic and overall lipid control was low in our study despite lipid-lowering therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-023-01522-z","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T07:02:32Z","timestamp":1701759752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-3542","authenticated-orcid":false,"given":"Shahjada","family":"Selim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-5641","authenticated-orcid":false,"given":"Muhammad Shah","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5240-8225","authenticated-orcid":false,"given":"Samir Kumar","family":"Talukder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-3376","authenticated-orcid":false,"given":"Md Lutful","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7334-9751","authenticated-orcid":false,"given":"Abu Jar","family":"Gaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4410-4808","authenticated-orcid":false,"given":"Md Ahamedul","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0657-5318","authenticated-orcid":false,"given":"Nusrat","family":"Zarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5426-0531","authenticated-orcid":false,"given":"Shahin Ibn","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8749-2575","authenticated-orcid":false,"given":"Md Masud Un","family":"Nabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8519-4988","authenticated-orcid":false,"given":"Marufa","family":"Mustari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2351-8879","authenticated-orcid":false,"given":"Md Firoj","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6093-3871","authenticated-orcid":false,"given":"Ahmed Ifrad Bin","family":"Raunak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2917-5982","authenticated-orcid":false,"given":"Md Azizul","family":"Hoque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2101-9694","authenticated-orcid":false,"given":"Md Rashedul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4488-9388","authenticated-orcid":false,"given":"Farhana","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3285-6343","authenticated-orcid":false,"given":"Mohammad Abdul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6121-1192","authenticated-orcid":false,"given":"Mohammad","family":"Saifuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-987X","authenticated-orcid":false,"given":"Md","family":"Asaduzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6101-3812","authenticated-orcid":false,"given":"Mohammad Motiur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1910-0613","authenticated-orcid":false,"given":"Afsar","family":"Ahammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Abdur","family":"Rafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Jahid","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5681-6522","authenticated-orcid":false,"given":"A. B. M.","family":"Kamrul-Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"1522_CR1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"1522_CR2","doi-asserted-by":"publisher","first-page":"108086","DOI":"10.1016\/j.diabres.2020.108086","volume":"162","author":"P Saeedi","year":"2020","unstructured":"Saeedi P, Salpea P, Karuranga S, Petersohn I, Malanda B, Gregg EW, et al. Mortality attributable to diabetes in 20\u201379 years old adults, 2019 estimates: Results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract. 2020;162:108086.","journal-title":"Diabetes Res Clin Pract"},{"key":"1522_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-019-1133-9","volume":"21","author":"T Htay","year":"2019","unstructured":"Htay T, Soe K, Lopez-Perez A, Doan AH, Romagosa MA, Aung K. Mortality and cardiovascular disease in type 1 and type 2 diabetes. Curr Cardiol Rep. 2019;21:1\u20137.","journal-title":"Curr Cardiol Rep"},{"key":"1522_CR4","first-page":"1","volume":"19","author":"R Jagannathan","year":"2019","unstructured":"Jagannathan R, Patel SA, Ali MK, Narayan KV. Global updates on cardiovascular disease mortality trends and attribution of traditional risk factors. Curr DiabRep. 2019;19:1\u201312.","journal-title":"Curr DiabRep"},{"key":"1522_CR5","doi-asserted-by":"publisher","first-page":"e016947","DOI":"10.1161\/JAHA.120.016947","volume":"10","author":"AD Kaze","year":"2021","unstructured":"Kaze AD, Santhanam P, Musani SK, Ahima R, Echouffo-Tcheugui JB. Metabolic dyslipidemia and cardiovascular outcomes in type 2 diabetes mellitus: findings from the look AHEAD study. J Am Heart Assoc. 2021;10:e016947.","journal-title":"J Am Heart Assoc"},{"key":"1522_CR6","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.metabol.2014.08.010","volume":"63","author":"L Wu","year":"2014","unstructured":"Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism. 2014;63:1469\u201379.","journal-title":"Metabolism"},{"key":"1522_CR7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.5551\/jat.RV17023","volume":"25","author":"T Hirano","year":"2018","unstructured":"Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb. 2018;25:771\u201382.","journal-title":"J Atheroscler Thromb"},{"key":"1522_CR8","doi-asserted-by":"publisher","first-page":"e2127573","DOI":"10.1001\/jamanetworkopen.2021.27573","volume":"4","author":"Y Lu","year":"2021","unstructured":"Lu Y, Zhang H, Lu J, Ding Q, Li X, Wang X, et al. Prevalence of dyslipidemia and availability of lipid-lowering medications among primary health care settings in china. JAMA Netw Open. 2021;4:e2127573\u2013e2127573.","journal-title":"JAMA Netw Open"},{"key":"1522_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-019-1034-3","volume":"18","author":"P Narindrarangkura","year":"2019","unstructured":"Narindrarangkura P, Bosl W, Rangsin R, Hatthachote P. Prevalence of dyslipidemia associated with complications in diabetic patients: a nationwide study in thailand. Lipids Health Dis. 2019;18:1\u20138.","journal-title":"Lipids Health Dis"},{"key":"1522_CR10","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/j.dsx.2019.06.009","volume":"13","author":"MJ Shahwan","year":"2019","unstructured":"Shahwan MJ, Jairoun AA, Farajallah A, Shanabli S. Prevalence of dyslipidemia and factors affecting lipid profile in patients with type 2 diabetes. Diabetes Metab Syndr. 2019;13:2387\u201392.","journal-title":"Diabetes Metab Syndr"},{"key":"1522_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-022-01691-1","volume":"21","author":"J Li","year":"2022","unstructured":"Li J, Nie Z, Ge Z, Shi L, Gao B, Yang Y. Prevalence of dyslipidemia, treatment rate and its control among patients with type 2 diabetes mellitus in northwest china: a cross-sectional study. Lipids Health Dis. 2022;21:1\u20139.","journal-title":"Lipids Health Dis"},{"key":"1522_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-021-00813-7","volume":"21","author":"L Pitso","year":"2021","unstructured":"Pitso L, Mofokeng TRP, Nel R. Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central south africa. BMC Endocr Disord. 2021;21:1\u201310.","journal-title":"BMC Endocr Disord"},{"key":"1522_CR13","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/ijcp.12238","volume":"67","author":"K Jameson","year":"2013","unstructured":"Jameson K, Amber V, D\u2019oca K, Mills D, Giles A, Ambegaonkar B. Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care\u2013a retrospective database study. Int J Clin Pract. 2013;67:1228\u201337.","journal-title":"Int J Clin Pract"},{"key":"1522_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s42000-018-0014-8","volume":"17","author":"VG Athyros","year":"2018","unstructured":"Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, et al. Diabetes and lipid metabolism. Hormones. 2018;17:61\u20137.","journal-title":"Hormones"},{"key":"1522_CR15","doi-asserted-by":"publisher","first-page":"e036086","DOI":"10.1136\/bmjopen-2019-036086","volume":"10","author":"S Akhtar","year":"2020","unstructured":"Akhtar S, Nasir JA, Sarwar A, Nasr N, Javed A, Majeed R, et al. Prevalence of diabetes and pre-diabetes in Bangladesh: a systematic review and meta-analysis. BMJ Open. 2020;10:e036086.","journal-title":"BMJ Open"},{"key":"1522_CR16","doi-asserted-by":"publisher","first-page":"e0000461","DOI":"10.1371\/journal.pgph.0000461","volume":"2","author":"MB Hossain","year":"2022","unstructured":"Hossain MB, Khan MN, Oldroyd JC, Rana J, Magliago DJ, Chowdhury EK, et al. Prevalence of, and risk factors for, diabetes and prediabetes in Bangladesh: evidence from the national survey using a multilevel poisson regression model with a robust variance. PLOS Global Public Health. 2022;2:e0000461.","journal-title":"PLOS Global Public Health"},{"key":"1522_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.dsx.2018.09.006","volume":"13","author":"H Das","year":"2019","unstructured":"Das H, Banik S. Prevalence of dyslipidemia among the diabetic patients in southern Bangladesh: a cross-sectional study. Diabetes Metab Syndr. 2019;13:252\u20137.","journal-title":"Diabetes Metab Syndr"},{"issue":"Suppl 1","key":"1522_CR18","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc23-S010","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Das SR, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Kosiborod M, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes-2023. Diabetes care. 2023;46(Suppl 1):S158\u201390. https:\/\/doi.org\/10.2337\/dc23-S010.","journal-title":"Diabetes care"},{"key":"1522_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-019-1246-1","volume":"21","author":"A Sillars","year":"2019","unstructured":"Sillars A, Sattar N. Management of lipid abnormalities in patients living with diabetes. Curr Cardiol Rep. 2019;21:1\u20138.","journal-title":"Curr Cardiol Rep"},{"key":"1522_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1741826711400545","volume":"19","author":"AK Gitt","year":"2012","unstructured":"Gitt AK, Drexel H, Feely J, Ferri\u00e8res J, Gonzalez-Juanatey JR, Thomsen KK, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol. 2012;19:221\u201330.","journal-title":"Eur J Prev Cardiol"},{"key":"1522_CR21","unstructured":"World Health Organization, International Association of Study of Obesity, International Obesity Task Force.\u00a0The Asia-Pacific Perspective. Redefining obesity and its treatment.\u00a02000.\u00a0\nhttp:\/\/www.wpro.who.int\/nutrition\/documents\/Redefining_obesity\/en\/. Accessed 10 June 2023."},{"key":"1522_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.diabres.2017.12.004","volume":"137","author":"K Khunti","year":"2018","unstructured":"Khunti K, Ceriello A, Cos X, De Block C. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2018;137:137\u201348.","journal-title":"Diabetes Res Clin Pract"},{"key":"1522_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S2213-8587(22)00072-9","volume":"10","author":"RM Anjana","year":"2022","unstructured":"Anjana RM, Unnikrishnan R, Deepa M, Venkatesan U, Pradeepa R, Joshi S, et al. Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in india (ICMR-INDIAB-13): a national cross-sectional study. Lancet Diabetes Endocrinol. 2022;10:430\u201341.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1522_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3949\/ccjm.87a.19078","volume":"87","author":"M Mirbolouk","year":"2020","unstructured":"Mirbolouk M, Blaha MJ. ACC\/AHA lipid guidelines: personalized care to prevent cardiovascular disease. Cleve Clin J Med. 2020;87:231.","journal-title":"Cleve Clin J Med"},{"key":"1522_CR25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.2174\/1570161115666170201105425","volume":"15","author":"T Filippatos","year":"2017","unstructured":"Filippatos T, Tsimihodimos V, Pappa E, Elisaf M. Pathophysiology of diabetic dyslipidaemia. Curr Vasc Pharmacol. 2017;15:566\u201375.","journal-title":"Curr Vasc Pharmacol"},{"key":"1522_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ecl.2006.06.002","volume":"35","author":"TJ Chahil","year":"2006","unstructured":"Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin. 2006;35:491\u2013510.","journal-title":"Endocrinol Metab Clin"},{"key":"1522_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-019-1170-9","volume":"18","author":"T Zhang","year":"2019","unstructured":"Zhang T, Chen J, Tang X, Luo Q, Xu D, Yu B. Interaction between adipocytes and high-density lipoprotein: new insights into the mechanism of obesity-induced dyslipidemia and atherosclerosis. Lipids Health Dis. 2019;18:1\u201311.","journal-title":"Lipids Health Dis"},{"key":"1522_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-018-0256-0","volume":"18","author":"J Jang","year":"2018","unstructured":"Jang J, Kim Y, Shin J, Lee SA, Choi Y, Park E-C. Association between thyroid hormones and the components of metabolic syndrome. BMC Endocr Disord. 2018;18:1\u20139.","journal-title":"BMC Endocr Disord"},{"key":"1522_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/2042018817692296","volume":"8","author":"A Hussain","year":"2017","unstructured":"Hussain A, Ali I, Ijaz M, Rahim A. Correlation between hemoglobin A1c and serum lipid profile in afghani patients with type 2 diabetes: hemoglobin A1c prognosticates dyslipidemia. Ther Adv Endocrinol Metab. 2017;8:51\u20137.","journal-title":"Ther Adv Endocrinol Metab"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01522-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-023-01522-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01522-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T07:03:12Z","timestamp":1701759792000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-023-01522-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1522"],"URL":"https:\/\/doi.org\/10.1186\/s12902-023-01522-z","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,5]]},"assertion":[{"value":"18 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received ethical permission from the institutional review board of Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh (Ref. no.: BSMMU\/2021\/4786\u2013211; Date: 20 November 2021). Informed written consent was taken from the study subjects. The all authors declare no human subjects were harmed and the procedures followed were in accordance with the ethical standards and regulations established by the Helsinki Declaration of the World Medical Association.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}